Exelixis Initiates Randomized Phase II Clinical Trial of Cabozantinib Plus Abiraterone in Chemotherapy-Naive Patients with Metastatic CRPC

“Exelixis, Inc. today announced that it has initiated a phase II clinical trial comparing cabozantinib plus abiraterone and prednisone (abiraterone/prednisone) versus abiraterone/prednisone in patients with castration-resistant prostate cancer (CRPC) who have bone metastases and have not been previously treated with chemotherapy. The primary endpoint for the randomized, open-label trial is radiographic progression-free survival (PFS).”